The data suggest that classic chemotherapy combined with TME-targeting agents can induce tumor responses more effectively than chemotherapy alone, with the efficacy of an EREG mAb even superior to that of cetuximab, an anti-EGFR agent widely used to restrain EGFR+ neoplastic cell expansion by inducing apoptosis in diverse malignancies [47]. The gene discussed is EGFR; the disease is neoplasm.